戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ibility of a sample-to-answer, point-of-care HPV DNA test.
2 vulvovaginal specimen collection for Pap and HPV DNA testing.
3 geal, and genital samples were collected for HPV DNA testing.
4  for minimally invasive, rapid, and scalable HPV DNA testing.
5 nation and self-collected anal specimens for HPV DNA testing.
6 lue, and negative predictive value, for TTMV-HPV DNA testing.
7  cancer screening with human papillomavirus (HPV) DNA testing.
8                         Compared with reflex HPV DNA testing, a strategy of repeat cervical cytology
9                                      Whether HPV DNA testing alone is useful in primary screening rem
10                                              HPV DNA testing among children included conjunctival, or
11 usly evaluated with the Digene HC2 high-risk HPV DNA test and found 95.4% concordance between the ass
12 -21 years were seen at 4-month intervals for HPV DNA testing and cytology.
13                     Women were screened with HPV DNA testing and cytology.
14 screening strategies that incorporate DVI or HPV DNA testing and eliminate colposcopy may offer attra
15 paring test performance metrics between TTMV-HPV DNA testing and fine-needle aspiration.
16       New and sensitive technologies such as HPV DNA testing and liquid-based cytology are more likel
17        Cervical and vulvovaginal samples for HPV DNA testing and Papanicolaou testing were collected
18 proach, combined with concurrent testing (hr-HPV DNA testing and visual inspection), holds promise fo
19 ing using high-risk human papillomavirus (hr-HPV) DNA testing and visual inspection methods, as well
20       Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collecte
21 tocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Pap
22 eening strategies (VIA, human papillomavirus HPV DNA testing, and Pap cytology) in a periurban commun
23  have been published this year on the use of HPV DNA testing as a primary screening modality and as a
24 ed cervical samples for cytology testing and HPV DNA testing at each visit.
25 luded patients with OPSCC who underwent TTMV-HPV DNA testing between April 2020 and September 2022 du
26 enter ASCUS-LSIL Triage Study has shown that HPV DNA testing can be used safely to minimize intervent
27                         Lowering the cost of HPV DNA testing could make more frequent screening finan
28                                     The TTMV-HPV DNA test demonstrated sensitivity of 88.4% (95% CI,
29  $381 590 per QALY for combined cytology and HPV DNA testing, depending on age and screening frequenc
30       The most intensive approach, involving HPV DNA testing every 5 years for women aged 35-60, achi
31  with a 5-year interval; and (4) introducing HPV DNA testing every 5 years for women aged 35-60.
32                                         TTMV-HPV DNA testing exhibited a sensitivity of 95.7% (95% CI
33                           The sensitivity of HPV DNA testing for HSIL was equivalent to, if not great
34 6 950 to $272 350 per QALY for cytology with HPV DNA testing for triage of equivocal results and from
35              Respondents reported ever using HPV DNA tests for both approved and nonapproved indicati
36  strategies that differ by test (cytology or HPV DNA testing), frequency, and start age versus screen
37 when strategies were compared incrementally, HPV DNA testing generally was more effective but also mo
38                                    Recently, HPV DNA tests have been developed for use in resource-li
39            Since 1999, human papillomavirus (HPV) DNA tests have been approved only for abnormal cerv
40 quencing and the Qiagen digene HC2 high-risk HPV DNA test (hc2), demonstrated overall positive agreem
41 d with current screening that uses sensitive HPV DNA testing, HPV vaccination is associated with less
42 ervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not be
43                          If the price of the HPV DNA test is reduced to $9 USD, the most frequent tes
44              High-risk human papillomavirus (HPV) DNA testing is widely acknowledged as the most sens
45 ion using clinician-collected anal swabs for HPV DNA testing obtained during a 1-year prospective stu
46 cation of 5% acetic acid, cervicography, and HPV DNA testing of a clinician-obtained cervical sample.
47              For women with ASCUS Pap tests, HPV DNA testing of residual specimens collected for rout
48 ntegrated strategy, comprising point-of-care HPV DNA testing of self-collected specimens and same-day
49                 The false-positive rates for HPV DNA testing of self-collected vaginal samples and Pa
50                        Human papillomavirus (HPV) DNA testing of women having Papanicolaou (Pap) smea
51                                              HPV DNA testing on self-collected vaginal and placental
52 y combined with vaccination; (2) introducing HPV DNA testing once between ages 35-40; (3) introducing
53      Persistence can be measured by repeated HPV DNA tests or by cytologic testing.
54 veillance cohort if they had at least 1 TTMV-HPV DNA test performed after completion of definitive or
55                                    To assess HPV DNA testing practices, we mailed surveys to 6906 ran
56                                       Reflex HPV DNA testing provides the same or greater life expect
57           The next least costly strategy was HPV DNA testing resulting in a reduction in total cancer
58 arance was defined as 2 consecutive negative HPV DNA test results.
59                                  We compared HPV DNA-testing results from 146 matched exfoliated-cell
60                 Although the introduction of HPV DNA testing significantly increases costs, a high fr
61 es, the assay could serve as a point-of-care HPV DNA test that improves access to cervical cancer scr
62                          H13 is a lower-cost HPV DNA test that might be useful for primary screening
63  median (range) lead time from positive TTMV-HPV DNA test to pathologic confirmation was 47 (0-507) d
64 ing once between ages 35-40; (3) introducing HPV DNA testing twice between ages 35-45, with a 5-year
65                                              HPV DNA testing typically requires complex lab infrastru
66       Interventions are needed to discourage HPV DNA test use for nonapproved indications.
67                                       Reflex HPV DNA testing uses either residual liquid-based cytolo
68 men without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube t
69                                              HPV DNA testing was also done on placental samples (swab
70                                      Vaginal HPV DNA testing was done on self-collected vaginal sampl
71                                              HPV DNA testing was done on vaginal samples collected du
72        Awareness (87%) and ever use (67%) of HPV DNA tests was high.
73 bosomal RNA gene amplicon pyrosequencing and HPV DNA testing were conducted annually in serial cervic
74 on Survey and had results of oral and penile HPV DNA testing were examined.
75 diated isothermal amplification (LAMP)-based HPV DNA test, which targets three of the most oncogenic
76  were obtained for liquid-based cytology and HPV DNA testing with two first-generation assays (Amplic